Thistle Resources (TSX-V:TRCG) announced that it has completed its qualifying transaction, allowing its shares to resume trading on the TSX Venture Exchange as a Tier 2 mining issuer.
The transaction, finalized through a three-cornered amalgamation, saw Thistle, formerly St. Davids Capital Inc., acquire all outstanding shares of Thistle Resources Corp. (TRC), which now operates as a wholly owned subsidiary.
Replenish Nutrients Holding Corp (CSE:ERTH, OTC:VVIVF, FRA:7KE) has reported its fourth-quarter and full-year 2025 financial results, highlighting progress in scaling its regenerative fertilizer platform alongside continued net losses as the company transitions toward commercialization.
For the fourth quarter ended December 31, 2025, revenue rose to $3 million from $2.6 million a year earlier, driven by higher fertilizer sales volumes and pricing.
Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) fell 12% to 7.71p after the group reported first-quarter revenue growth and positive earnings but flagged potential headwinds in the US market and announced the departure of its finance chief.
The pharmaceutical company, which focuses on iron deficiency treatments, said group net revenues rose to $18 million in the quarter, up from $7 million a year earlier, with EBIT of about $2.5 million compared to a $4.4 million loss previously.
Union Jack Oil PLC (AIM:UJO, OTCQB:UJOGF, FRA:1UJ0) said the rig for the Crossroads Well in Southern Oklahoma remains under maintenance and repair, pushing the next drilling timetable marker into early May.
The AIM-listed onshore hydrocarbon company said operator Reach Oil and Gas Company Inc had informed it that a spud date would be provided in early May.
Resolution Minerals Ltd (ASX:RML, OTCQB:RLMLF, FRA:NC3) last week outlined plans to accelerate development at its Horse Heaven Project in Idaho following a successful $20 million capital raise backed by institutional investors.
Chief executive of US operations Craig Lindsay said the placement, supported by Tribeca Investment Partners and L1 Capital Global Opportunities Master Fund, was achieved despite challenging market conditions. He noted that the company was “really happy to raise $20 million” and highlighted improved pricing relative to recent trading levels, reflecting renewed investor confidence.
Riversgold Ltd (ASX:RGL, FRA:RGV, OTC:RVSGF) has advanced development plans at its Northern Zone Gold Project near Kalgoorlie during the March quarter, underpinned by a funding and mining agreement that removes up-front capital requirements and supports a pathway towards production.
Work at the project, located about 25 kilometres east of Kalgoorlie, focused on progressing approvals, expanding tenure and continuing drilling to define a growing gold system.
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has secured $265,000 through a share purchase plan (SPP), adding to a broader $20 million capital raising as the company shifts its focus towards commercial expansion of its FebriDx diagnostic platform.
The SPP, which closed on April 24, attracted applications for 1,177,770 new shares at $0.225 each, with participation from existing shareholders including directors Sam Lanyon and Catherine Robson.
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has reported Q3 FY2026 operational progress across its anti-infective pipeline, led by a second US Army research agreement, continued dosing in its Indonesian Phase 3 trial and expanded patent protection in Brazil.
Resolution Minerals Ltd (ASX:RML, OTCQB:RLMLF, FRA:NC3) has advanced exploration and development work at its 100%-owned Horse Heaven Gold-Antimony-Tungsten-Silver Project in Idaho, USA, during the March quarter.
Rock sampling at Antimony Ridge returned assays of up to 48.7% antimony and 890 g/t silver, confirming a high-grade polymetallic system across the historical mine area.